Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AVANT Immunotherapeutics Inc. (Nasdaq: AVAN) -- Ignore unavailable to you. Want to Upgrade?

To: SemiBull who wrote (456)	5/20/2003 8:53:51 PM
From: SemiBull	Read Replies (1) \| Respond to of 513

2:15PM Avant Immun -- New High Profile (AVAN) 1.64 +0.17: Microcap name Avant Immunotherapeutics hit a new 52-week high today on almost 2x avg daily volume; the co is developing a broad portfolio of vaccines addressing bacterial and viral diseases, cardiovascular disease, food safety, and biodefense (in Jan the shares surged after the co was awarded a Defense Dept subcontract to develop the first oral, combination vaccine against plague and anthrax). In its most recent qtr, the co narrowed its loss to $0.06 on $682k in sales. Mkt cap: $97 mln, float: 60.4 mln shares, avg daily volume: 412k shares. finance.yahoo.com